Vistagen Therapeutics Inc.
VTGN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.47M
Close$
$0.72
325.1% upside
Current Fair Value
325.1% upsideUndervalued by 325.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.47 Million |
|---|---|
| Enterprise Value | $-8,505,368.00 |
| Earnings per Share | $-1.83 |
| Beta | 0.39 |
| Outstanding Shares | 42,980,174 |
Return
| Return on Equity | -276.21% |
|---|---|
| Return on Assets | -189.22% |
| Return on Invested Capital | -283.29% |
Valuation & Multiples
| P/E Ratio | -0.1 |
|---|---|
| PEG | 0.72 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -3.4 |
| Enterprise Value to EBIT | 0.12 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.12 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.36
Consensus analyst estimateRevenue Estimate
$500,000
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.38
Consensus analyst estimateRevenue Estimate
$500,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 7.16% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 27.40% |
|---|---|
| Total Invested | $9▼ 100.00% |
| Investors Holding | 1▼ 57.00% |
About VistaGen Therapeutics Inc
21 employees
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CN...